Peptide HER2(776–788) represents a naturally processed broad MHC class II-restricted T cell epitope
| Title: | Peptide HER2(776–788) represents a naturally processed broad MHC class II-restricted T cell epitope |
|---|---|
| Authors: | Avgi Mamalaki, Constantin N. Baxevanis, Michael Papamichail, Sonia A. Perez, Graham Pawelec, Panagiota A. Sotiropoulou, R Sotiriadou, Hartmut Echner, Susanne Heinzel, Wolfgang Voelter, Angelos D. Gritzapis |
| Source: | British Journal of Cancer British Journal of Cancer, 85 (10 |
| Publisher Information: | Springer Science and Business Media LLC, 2001. |
| Publication Year: | 2001 |
| Subject Terms: | Cancer Research, Oncology, MHC class I, biology.protein, biology, Antigen presentation, T cell, medicine.anatomical_structure, medicine, Antigen, Major histocompatibility complex, Epitope, Cytotoxic T cell, MHC class II, Virology, skin and connective tissue diseases, Regular Article, HER-2/neu peptide, CD4+ T cell clones, MHC alleles, vaccines, cancer immunotherapy, Sciences bio-médicales et agricoles, Antigen Presentation, Antigens, Neoplasm -- immunology, Cell Line, Cells, Cultured, Clone Cells, Epitopes, T-Lymphocyte -- immunology, HLA-DR Antigens -- physiology, Humans, Interferon-gamma -- biosynthesis, Lymphocyte Activation, Neoplasms -- immunology, Peptide Fragments -- immunology, Peptides -- immunology, Receptor, erbB-2 -- immunology, T-Lymphocytes, Cytotoxic -- immunology, Tumor Cells, Cultured |
| Description: | HER2/neu-derived peptides inducing MHC class II-restricted CD4+ T helper lymphocyte (Th) responses, although critical for tumour rejection, are not thoroughly characterized. Here, we report the generation and characterization of CD4+ T cell clones specifically recognizing a HER-2/neu-derived peptide (776-788) [designated HER2(776-788)]. Such clones yielded specific proliferative and cytokine [gamma-interferon(IFN)-gamma] responses when challenged with autologous dendritic cells (DCs) loaded with HER2(776-788). By performing blocking studies with monoclonal antibodies (MAbs) and by using DCs from allogeneic donors sharing certain HLA-DR alleles, we found that HER2(776-788) is a promiscuous peptide presented, at least, by DRB5*0101, DRB1*0701 and DRB1*0405 alleles. One TCRV beta 6.7+ clone recognized the HLA-DRB5*0101+ FM3 melanoma cell line transfected with a full length HER-2/neu cDNA. Moreover, this clone recognized the HER-2/neu+ SKBR3 breast cancer cell line induced to express HLA-DR, thus demonstrating that HER2(776-788) represents a naturally processed and presented epitope. Our data demonstrate that helper peptide HER2(776-788) represents a promiscuous epitope binding to at least three HLA-DR alleles, thus offering a broad population coverage. The use of antigenic peptides presented by major histocompatibility complex (MHC) class II in addition to those presented by class I may improve the therapeutic efficacy of active immunization. Journal Article Research Support, Non-U.S. Gov't info:eu-repo/semantics/published |
| File Description: | 1 full-text file(s): application/pdf |
| ISSN: | 1532-1827 0007-0920 |
| Access URL: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5c064cbd2aea380c07af5715e2ac6a1 https://doi.org/10.1054/bjoc.2001.2089 |
| Rights: | OPEN |
| Accession Number: | edsair.doi.dedup.....b5c064cbd2aea380c07af5715e2ac6a1 |
| Database: | OpenAIRE |
| ISSN: | 15321827 00070920 |
|---|